The clinical effectiveness of individual behaviour change interventions to reduce risky sexual behaviour after a negative human immunodeficiency virus test in men who have sex with men: systematic and realist reviews and intervention development Evidence regarding the effectiveness of behaviour change interventions suggests that they are effective in changing behaviour associated with HIV transmission. Exploratory stratified meta-analyses suggested that interventions should be delivered face to face and immediately after testing. There are uncertainties around the generalisability of these findings to the UK setting. However, UK experts found the intervention acceptable and provided ways of optimising the candidate intervention. Health Technology Assessment
NG63 Antimicrobial stewardship: changing risk-related behaviours in the general population
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people's behaviour to reduce antimicrobial resistance and the spread of resistant microbes. NICE Guidance Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/ng63 TA429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation Ibrutinib alone is recommended as an option for treating chronic lymphocytic leukaemia in adults who have had at least 1 prior therapy or who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable. NICE Technology Appraisal Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/ta429 TA430 Sofosbuvir-velpatasvir for treating chronic hepatitis C Sofosbuvir-velpatasvir is recommended as an option for treating chronic hepatitis C in adults, for HCV genotypes 1-6. For HCV-2 without cirrhosis, it is only recommended for patients who cannot tolerate interferon or for whom interferon is unsuitable. NICE Technology Appraisal Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/ta430 TA431 Mepolizumab for treating severe refractory eosinophilic asthma Mepolizumab, as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults, only if conditions regarding blood eosinophil count, repeated exacerbations, and need for continuous oral corticosteroids are met. NICE Technology Appraisal Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/ta431 CG62 Antenatal care for uncomplicated pregnancies This guideline covers the care that healthy women and their babies should be offered during pregnancy. It aims to ensure that pregnant women are offered regular checkups, information and support. NICE Clinical Guideline Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/cg62
ES4 Refractory extrapulmonary sarcoidosis: infliximab
This evidence summary includes 10 observational studies that assessed the effects of infliximab for treating active, unstable extrapulmonary sarcoidosis in people who had found corticosteroids and other immunosuppressants to be ineffective, or who could not tolerate these treatments (refractory sarcoidosis). Extrapulmonary sarcoidosis resolved in a third and improved in around half of cases. Infliximab may be an option for some patients with severe, refractory extrapulmonary sarcoidosis (particularly cutaneous or neurological sarcoidosis); for example, those affected by disabling or disfiguring disease, or whose life expectancy is likely to be reduced.
NICE Evidence Summary
Systematic search: Yes January 2017 https://www.nice.org.uk/advice/es4/chapter/Key-points-from-the-evidence TA427Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib Pomalidomide, in combination with low-dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib, NICE Technology Appraisal Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/ta427
TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab is recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]-or anaplastic lymphoma kinase [ALK]-positive tumour), only if pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression. NICE Technology Appraisal Systematic search: Yes January 2017 https://www.nice.org.uk/guidance/ta428
EPPI Centre Nil

AHRQ (Agency for Healthcare Research and Quality -USA)
Glasgow Coma Scale for Field Triage of Trauma: A Systematic Review
The total GCS is associated with slightly greater discrimination than the motor component of GCS or simplified motor scale (SMS) for in-hospital mortality, receipt of neurosurgical interventions, severe brain injury, and emergency intubation, with differences in the AUROC ranging from 0.01 to 0.05. The clinical significance of small differences in discrimination is likely to be small, and could be offset by factors such as convenience and ease of use. AHRQ Research Synthesis Systematic search: Yes January 2017 https://www.effectivehealthcare.ahrq.gov/ehc/products/635/2416/field-triageglasgow-executive-170112.pdf
Tonsillectomy for Obstructive Sleep-Disordered Breathing (OSDB) or Recurrent Throat Infection in Children
